MW 652.7 Da, Purity >98%. Z-VEID-FMK, caspase-6 inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
MW 652.7 Da, Purity >98%. Z-VEID-FMK, caspase-6 inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
This product is manufactured by BioVision, an Abcam company and was previously called 1011 Caspase-6 Inhibitor Z-VEID-FMK. 1011-20C is the same size as the 20 μl size of ab142025.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab142025, Z-VEID-FMK, caspase-6 inhibitor
SHSY5Y cells were incubated at 37 °C for 1h with vehicle control (0 μM) and 1 μM of Z-VEID-FMK (ab142025). After this incubation 10µM of camptothecin (Camptothecin, DNA topoisomerase inhibitor ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic SHSY5Y cells correlates with an increase in Z-VEID-FMK concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab37722 at 1 μg/ml and Anti-beta Actin antibody ab8227 at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/10000 dilution and visualised using ECL development solution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com